


The Fund will seek capital appreciation.
| Name | % Net Assets | 
|---|---|
| CELGENE CORP | 9.4% | 
| GILEAD SCIENCES INC | 7.7% | 
| GENENTECH INC | 7.1% | 
| GENZYME CORP-GENERAL DIVISION | 6.5% | 
| AMGEN INC | 4.6% | 
| PDL BIOPHARMA INC | 3.9% | 
| BIOGEN IDEC INC | 3.5% | 
| VERTEX PHARMACEUTICALS INC | 2.6% | 
| MYRIAD GENETICS INC | 2.1% | 
| INDEVUS PHARMACEUTICALS INC | 1.8% | 
| Key | % Net Assets | 
|---|---|
| 9.4% | |
| 7.7% | |
| 7.1% | |
| 6.5% | |
| 69.3% | 
| Date | n/a | 
|---|---|
| Bid | 0.00 | 
| Offer | 0.00 | 
| Currency | n/a | 
| Change | 0.00 | 
| % | n/a | 
| YTD change | 0.00 | 
| YTD % | n/a | 
| Fund Inception | 10/07/2000 | 
|---|---|
| Fund Manager | Evan McCulloch / Vincent Xiang | 
| TER | 1.73 (30-Nov-2011) | 
| Minimum Investment | |
|---|---|
| Initial | 1000 | 
| Additional | 250 | 
| Savings | 50 | 
| Charges | |
|---|---|
| Initial | 5.00% | 
| Annual Mang't | 1.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.02 | 
| Sharpe ratio | -0.14 | 
You are here: research